Versant Ventures

Founded 1999
Founders Barbara Lubash Brian Atwood Donald B. Milder Rebecca Robertson Samuel Colella William Link

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 308
Average round size
info
The average size of a deal this fund participated in
$30M
Portfolio companies 157
Rounds per year 14.00
Lead investments 45
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.52
Exits 77
Key employees 13
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Medical Device
  • Therapeutics
Summary

In 1999 was created Versant Ventures, which is appeared as VC. The main office of represented VC is situated in the Menlo Park. The fund was located in North America if to be more exact in United States.

The current fund was established by Barbara Lubash, Brian Atwood, Donald B. Milder, Rebecca Robertson, Samuel Colella, William Link. Besides them, we counted 13 critical employees of this fund in our database.

Speaking about the real fund results, this VC is 5 percentage points more often commits exit comparing to other organizations. The average startup value when the investment from Versant Ventures is 50-100 millions dollars. The important activity for fund was in 2008. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 13-24 deals every year. This Versant Ventures works on 5 percentage points less the average amount of lead investments comparing to the other organizations. The top amount of exits for fund were in 2018.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Versant Ventures, startups are often financed by OrbiMed, Investor Growth Capital Limited, Frazier Healthcare Partners. The meaningful sponsors for the fund in investment in the same round are Pequot Capital, Novartis Venture Fund, Kleiner Perkins. In the next rounds fund is usually obtained by Kleiner Perkins, Novartis Venture Fund, Abingworth.

Among the most popular portfolio startups of the fund, we may highlight Audentes Therapeutics, Pharmion, Kythera Biopharmaceuticals. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Medical Device, Life Science.

Read more

Funds with similar focus

Funds from United States, Menlo Park
Funds with similar focus located in United States, Menlo Park:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Jnana

Biotechnology
Health Care
Therapeutics
1
$50M18 Aug 2021 United States, Boston

T-knife

Biotechnology
1
$110M02 Aug 2021 Germany, Berlin

Turnstone Biologics

Biotechnology
Innovation Management
Therapeutics
1
$80M14 Jul 2021 United States, San Francisco

LENZ Therapeutics

Medical
Pharmaceutical
Therapeutics
1
$47M17 Jun 2021 United States, Coronado

Bright Peak Therapeutics

Biotechnology
Therapeutics
1
$107M10 Jun 2021 Switzerland, Basel

Capsida

Biotechnology
Genetics
Health Care
1
$50M29 Apr 2021 United States, Thousand Oaks

Biotechnology
Life Science
1
$100M08 Apr 2021 United States, " United States"}

Biotechnology
Medical
Therapeutics
1
$95M12 Mar 2021 Switzerland, Basel

Biotechnology
Health Care
Health Diagnostics
Therapeutics
1
$160M03 Mar 2021 United States, Philadelphia
News
858 Therapeutics Launches with Proven Team and $60 Million Series A Financing

– 858 Therapeutics has raised $60m in Series A financing.
– The round was led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
– 858 is a biotechnology company developing novel therapeutics for the treatment of cancer.
– The company’s lead program is a novel small molecule inhibitor of the PI3K/mTOR pathway that is being developed for the treatment of solid tumors that are resistant to existing therapies.
– The Series A proceeds will allow 858 to enter the clinic with its lead candidates that have potential to treat cancers that are resistant to current therapies.

iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases

– iECURE (pronounced EE-ah-cure), a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, announced it has closed a $50m Series A financing led by Versant Ventures and OrbiMed Advisors.
– The funds will be used to advance iECURE’s pipeline of up to 13 programs, all of which benefit from gene editing and in vivo delivery approaches being developed in the laboratory of James Wilson, M.D., Ph.D., of the University of Pennsylvania Gene Therapy Program (GTP).
– iECURE’s approach focuses on the mutation-agnostic in vivo insertion of healthy copies of disease-causing genes, with an initial focus in liver disorders.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Versant Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: